Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) tinted gains of +0.24% (+0.01 points) to US$4.21. The volume of 1.26 Million shares climbed up over an trading activity of 1.19 Million shares. EPS ratio determined by looking at last 12 month figures is -0.78. Over the same time span, the stock marked US$9.42 as its best level and the lowest price reached was US$3.62. The corporation has a market cap of US$360.38 Million.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s earnings per share has been growing at a 5.3 percent rate over the past 5 year when average revenue increase was noted as -3.6 percent. The return on equity ratio or ROE stands at -73.7 percent while most common profitability ratio return on investment (ROI) was -44.6 percent. The company’s institutional ownership is monitored at 85.2 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.6. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Thor Industries, Inc. (NYSE:THO) is worth US$3.4 Billion and has recently fallen -0.97% to US$64.64. The latest exchange of 0.63 Million shares is below its average trading activity of 993.94 Million shares. The day began at US$65.28 but the price moved to US$64.6 at one point during the trading and finally capitulating to a session high of US$66.08. The stock tapped a 52-week high of US$127.56 while the mean 12-month price target for the shares is US$81.25.
Currently, the stock carries a price to earnings ratio of 14.53, a price to book ratio of 1.79, and a price to sales ratio of 0.47. For the past 5 years, the company’s revenue has grown 20.8%, while the company’s earnings per share has grown 24.8%. With an institutional ownership near 93%, it carries an earnings per share ratio of 4.45.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 6 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.73.